A Philadelphia jury has handed up a defense verdict in favor of Bayer and Janssen Pharmaceuticals, finding that the label on the blood thinner Xarelto adequately warned patients about the danger of severe bleeds.

The jury, deliberating in the second Xarelto trial to come before a Philadelphia Court of Common Pleas jury, rendered its verdict Friday morning, after more than two weeks of trial and about two days of deliberation.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]